Stock Financial Ratios

XXII / 22nd Century Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)345.31
Enterprise Value ($M)384.57
Book Value ($M)24.33
Book Value / Share0.30
Price / Book13.73
NCAV ($M)10.92
NCAV / Share0.14
Price / NCAV371.52
Income Statement (mra) ($M)
Net Income-11.58
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio0.07
Current Ratio1.02
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.48
Return on Assets (ROA)-0.82
Return on Equity (ROE)-0.48
Identifiers and Descriptors
Central Index Key (CIK)1347858
Industry Groups
SIC 2111 - Cigarettes
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)0.00
Scoring Models
Piotroski F Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Liabilities Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Cash Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Liabilities Current Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Cash And Equivalents Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Assets Current Per Share0.00
Minority Interest Per Share0.00

Stock Research Report

22nd Century Group is a plant biotechnology company focused on (i) potentially reduced risk tobacco cigarettes and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding, and (ii) research and development of unique cannabis/hemp plants through genetic engineering and plant breeding to alter levels of cannabinoids for new medicines and improved agricultural uses. The company has an extensive intellectual property portfolio of issued patents and patent applications relating to the tobacco and cannabis plants. Its management team is focused on monetizing its intellectual property portfolio, obtaining regulatory approval to market both its reduced exposure cigarettes and its smoking cessation product in development, and developing and commercializing high value products derived from its unique cannabis/hemp plants. Additional information about its business and operations is contained in tis Annual Report on ...

Click for full article

Related News Stories

Value And Momentum Breakouts - 2017 End Of Year Report Card And Forecast

2017-12-17 seekingalpha
A look at the 2017 performance of the Value & Momentum Breakout portfolios from the best +70.50% to the worst -8.52%. (509-8)

2 More Small Caps For The Small Caps Season

2017-12-12 seekingalpha
Here are two more small cap companies which had a good 2017 but the shares have pulled back lately. (383-11)

SHU Puppies, The Best Smallcaps For Smallcap Season

2017-12-06 seekingalpha
We're about to enter the season for smallcaps, where they often gain most of the returns for the year. (382-8)

22nd Century Group Is A Great Long Play

2017-11-21 seekingalpha
22nd Century Group (NYSEMKT:XXII) is a plant biotechnology company that specializes in genetic engineering and plant breeding. The company develops technology to increase or decrease nicotine levels through genetic engineering and plant breeding, as well as cannabinoids levels in cannabis plants. The company was founded in 2011 and operates out of Clarence, NY. (381-4)

22nd Century Could See Its Stock Soar On The Latest Developments

2017-11-17 seekingalpha
The FDA mandated lower nicotine levels in tobacco, which 22nd Century already has developed patents on. (381-4)

CUSIP: 90137F103